The study examined formularies for 47 state Medicaid programs in the first quarter of 2023.
Ten states covered Saxenda or Wegovy, the two GLP-1 drugs approved for weight loss. Five of those states restricted coverage of the drugs through non-prefered status, prior authorization or step therapy.
Most states, 39, covered Ozempic, Victoza or Trulicity, GLP-1 drugs approved to treat diabetes.
Some states and employers have been hesitant to cover GLP-1 drugs, which come with a list price of up to $15,000 annually.
These states offer unrestricted coverage of Wegovy and Saxenda in Medicaid, as of 2023:
- California
- Delaware
- Minnesota
- Rhode Island
- Virginia
These states offer restricted coverage of Wegovy and Saxenda:
- Georgia (Saxenda only)
- Michigan
- New Hampshire
- Pennsylvania
- Wisconsin
The study was conducted by researchers at Beth Israel Deaconess Medical Center and Brigham and Women’s Hospital in Boston. See the full study here.
At the Becker's 5th Annual Fall Payer Issues Roundtable, taking place November 2–3 in Chicago, payer executives and healthcare leaders will come together to discuss value-based care, regulatory changes, cost management strategies and innovations shaping the future of payer-provider collaboration. Apply for complimentary registration now.